Search results for "hypoglycemic"

showing 5 items of 215 documents

Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants.

2007

Non-neuronal acetylcholine (ACh) is released from the human placenta into the extracellular space via organic cation transporters (OCTs). The present experiments investigated whether ACh release from epithelial cells is affected by drugs which are substrates of OCTs. The antidepressant drugs amitriptyline and doxepine were tested as both substances are not approved for pregnant women but frequently used. Release of ACh was measured in 10 min intervals over a period of 100 min. Test substances were added from t=50 min of incubation onwards. The effect was calculated by comparing the ACh release of the last three samples (t=70-100 min; B2) with that immediately before the application of the t…

medicine.medical_specialtyTime FactorsAmitriptylinePlacentaVasodilator AgentsPharmacologyIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyTheophyllinePregnancyInternal medicinemedicineExtracellularHumansHypoglycemic AgentsAmitriptylineGeneral Pharmacology Toxicology and PharmaceuticsIncubationNeuronsOrganic cation transport proteinsbiologyDose-Response Relationship DrugChemistryHuman placentaGeneral MedicineAcetylcholineAntidepressive AgentsMetforminNon neuronal acetylcholineEndocrinologybiology.proteinMinoxidilAntidepressantFemaleDoxepinAcetylcholinemedicine.drugLife sciences
researchProduct

Insulin resistance and polycystic ovary syndrome.

2008

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in humans, affecting approximately 7-8% of women of reproductive age. Despite the criteria adopted, PCOS is considered to be a predominantly hyperandrogenetic syndrome and the evaluation of metabolic parameters and insulin sensitivity is not mandatory. Most women with PCOS also exhibit features of the metabolic syndrome, including insulin resistance, obesity and dyslipidaemia. While the association with type 2 diabetes is well established, whether the incidence of cardiovascular disease is increased in women with PCOS remains unclear. Acknowledging the strong impact of insulin-resistance in the genesis of PCOS co…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Type 2 diabetesDiseaseEnvironmentBioinformaticsSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsGenetic Predisposition to DiseaseNutrition and Dieteticsbusiness.industryIncidenceHyperandrogenismnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryObesityfemale genital diseases and pregnancy complicationsEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesFemaleInsulin resistance pcosMetabolic syndromeInsulin ResistanceCardiology and Cardiovascular MedicinebusinessPolycystic Ovary SyndromeNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Pharmacotherapy for gestational diabetes

2018

Introduction: Gestational diabetes mellitus (GDM) represents impaired carbohydrate metabolism during pregnancy and is characterized by progressive insulin resistance and compensatory hyperinsulinaemia. If inadequately treated, it may lead to fetal macrosomia and other adverse outcomes. Areas covered: In this review, the authors summarize the current evidence from studies on the use of insulin and other agents for the treatment of women with GDM. Expert opinion: Lifestyle management is of paramount importance for the treatment of GDM. In pharmacotherapy, insulin remains the long-established mainstay of treatment. NPH (Neutral Protamine Hagedorn) and soluble human insulin have long been estab…

medicine.medical_specialtyinsulinlifestyleendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismCarbohydrate metabolism03 medical and health sciences0302 clinical medicineInsulin resistancePharmacotherapyPregnancyInternal medicineHumansMedicineHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineDipeptidyl-Peptidase IV InhibitorsPharmacologyDipeptidyl-Peptidase IV InhibitorsPregnancytherapybusiness.industryInsulinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseincretinPregnancy ComplicationPregnancy ComplicationsGestational diabetesDiabetes GestationalEndocrinologyGestational diabeteDipeptidyl-Peptidase IV InhibitorFemalebusiness
researchProduct

Continuous subcutaneous Insulin infusion leads to immediate, table, and long-term changes in metabolic control

2008

Background:  Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre- and one post-CSII measurement to assess metabolic therapy outcome. Aim:  Extending this research, the aim of the present study was to provide a more fine-grained analysis of achieved glycaemic control. Methods:  In 52 patients with type 1 diabetes (mean age of 37.85 years at CSII begin; s.d. ± 12.41), haemoglobin A1c (HbA1c) levels were assessed every 3 months over a period of 5 years (1 year before and 4 years after the introduction of CSII). Mixed models were utilized to describe changes in glycaemic control. Results:  The pre–post course showed that already in the first quarter, a statis…

mixed modelsAdultBlood GlucoseMalemedicine.medical_specialtyPediatricstype 1 diabetesEndocrinology Diabetes and MetabolismModels BiologicalDrug Administration ScheduleTimeHba1c levelEndocrinologyDiabetes mellitusInternal Medicinemedicinefollow upHumansHypoglycemic AgentsInsulinAge of OnsetGlycated HemoglobinType 1 diabetesHaemoglobin A1cbusiness.industry10093 Institute of PsychologyCSIIMean ageInfusion Pumps ImplantableMiddle AgedPrognosismedicine.diseaseSubcutaneous insulinSurgery1310 Endocrinologylong-term changes2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 1Treatment Outcome2724 Internal MedicineMetabolic control analysisFemalebusiness150 PsychologyFollow-Up StudiesMetabolic therapy
researchProduct

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study a…

2017

Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of pa…

randomized controlled trial; real-life; retrospective study; sodium glucose co-transporter-2 inhibitor; medicine (miscellaneous); endocrinology; diabetes and metabolism; nutrition and dietetics; cardiology and cardiovascular medicineBlood GlucoseTime FactorsGlucosideGlycated Hemoglobin ATime FactorMedicine (miscellaneous)Settore MED/13 - EndocrinologiaEndocrinologyGlucosidesSodium-Glucose Transporter 2Retrospective StudieDiabetes MellitusHumansHypoglycemic AgentsData MiningBenzhydryl CompoundsRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSodium-Glucose Transporter 2 InhibitorsRetrospective StudiesGlycated HemoglobinBenzhydryl CompoundNutrition and DieteticsEvidence-Based MedicineHypoglycemic AgentSodium-Glucose Transporter 2 InhibitorRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based MedicineReal-lifeBiomarkerDiabetes and MetabolismRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineRetrospective studyTreatment OutcomeDiabetes Mellitus Type 2ItalyRandomized controlled trialResearch DesignSodium glucose co-transporter-2 inhibitorCrowdsourcingCardiology and Cardiovascular MedicineBiomarkersType 2Human
researchProduct